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Objective: This study evaluated outcomes of remote endarterectomy (RE) vs endovascular (ENDO) interventions on
TransAtlantic Inter-Societal Consensus (TASC)-II D femoropopliteal lesions and identified factors predictive of
restenosis.
Methods: FromOctober 2004 to December 2008, 95 patients with TASC-II D lesions were randomized 1:1 to receive RE
of the superficial femoral artery (SFA) with end point stenting (51 patients) or ENDO, consisting of subintimal
angioplasty with stenting (44 patients). The groups were balanced for age, sex, atherosclerotic risk factors, and
comorbidities. Categoric data were analyzed with 2 tests, and time to event provided two-sided P values with a level of
significance at .05 and 95% confidence intervals (CIs). Survival curves for primary patency were plotted using the
Kaplan-Meier method. Univariate analysis for diabetes, hypertension, dyslipidemia, smoking, and critical ischemia was
performed according to the Cox proportional hazards model.
Results: The mean follow-up was 52.5 months (range, 35-75 months). Five RE patients and four ENDO patients were
lost to follow-up (censored). Primary patency was 76.5% (39 of 51) in RE and 56.8% (25 of 44) in ENDO (hazard ratio
[HR], 2.6; 95% CI, 0.99-4.2; P  .05) at 24 months and was 62.7% (32 of 46) in RE and 47.7% (21 of 40) in ENDO
(HR, 1.89; 95% CI, 0.94-3.78; P  .07) at 36 months. Assisted primary patency was 70.6% (36 of 51) in RE and 52.3%
(23 of 44) in ENDO (HR, 2.45; 95% CI, 1.20-5.02; P  .01). Secondary patency overlapped the primary comparison
data at 12 and 24 months; at 36 months, there was a slight but significative advantage for RE (HR, 2.26; 95% CI,
1.05-4.86; P  .03). Univariate analysis demonstrated that hypercholesterolemia and critical limb ischemia (CLI) were
significantly related to patency failure, whereas diabetes was significant only in ENDO. These factors (hypercholesterol-
emia and CLI) were independent predictors of patency on Cox multivariate analysis.
Conclusions: RE is a safe, effective, and durable procedure for TASC-II D lesions. Our data demonstrate a significantly
higher primary, assisted primary, and secondary patency of RE vs ENDO procedures. Furthermore, overall secondary
patency rates remain within the standard limits, although preoperative CLI and dyslipidemia continue to be associated
with worse outcomes. Taken together, these data suggest that RE should be considered better than an endovascular
procedure in SFA long-segment occlusion treatment. (J Vasc Surg 2012;56:1598-605.)
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tible to atherosclerotic disease. The traditional approach
involves conservative measures (smoking cessation, risk
factor modification, exercise, and pharmacologic ther-
apy) in patients with intermittent claudication1-3 and
surgical or endovascular approaches in those with severe
claudication or extensive occlusive disease and limb-
threatening ischemia.4,5
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1598The TransAtlantic Inter-Societal Consensus (TASC)-II
ocument6 recommends the endovascular procedure (an-
ioplasty or stenting, or both) as the treatment of choice for
emoropopliteal occlusive lesions up to 10 cm in length and
raditional surgical therapy for chronic total occlusions of
ommon femoral artery or SFA (20 cm, involving the
opliteal artery) or chronic total occlusion of popliteal
rtery and proximal trifurcation vessels (TASC-II D).
The subintimal technique has significantly contributed
o improving results, allowing the treatment of most com-
lex occlusive lesions solely with an endovascular approach
nd resulting in patients recovering functional status in a
horter time, with consequent benefit in costs.7 However,
esion length has been identified as an independent risk
actor for development of restenosis after angioplasty or
tenting, or both.8,9
Remote endarterectomy (RE) of the superficial femoral
nd external iliac arteries through a small groin incision
hen extensive disease is present allowed a significant im-
rovement in results.10-14 So far, no data have been pub-
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Volume 56, Number 6 Gabrielli et al 1599lished comparing RE and percutaneous transluminal angio-
plasty (PTA) with stent placement in SFA occlusion, and
scant information is known on optimal patient selection
criteria. This study investigated surgical outcomes of pri-
mary and secondary patency of RE and endovascular inter-
vention (angioplasty and stenting) in the treatment of more
complex TASC-II D femoropopliteal lesions. The study
aimed to determine which risk factors had significance in
predicting restenosis.
METHODS
Patients. From October 2004 to December 2008, 95
patients with Rutherford 3 to 5 TASC-II D lesions were
enrolled in a prospective randomized (1:1) trial. Of these,
51 underwent RE of SFA with end point stenting and 44
patients received subintimal angioplasty and stent place-
ment (ENDO). No additive interventions were performed
such as atherectomy, cryoplasty, or angioplasty alone.
Inclusion criteria were severe lifestyle-limiting claudica-
tion (Rutherford category 3) in 41 patients (20 RE and 21
ENDO), critical limb ischemia (CLI) (Rutherford category
4) in 41 patients (23 RE and 18 ENDO), or gangrene
(Rutherford category 5) in 13 patients (eight RE and five
ENDO). Exclusion criteria were previous treatment (endo-
vascular intervention or bypass), chronic renal insufficiency
(serum creatinine 1.5 mg/dL), and occlusion of iliac,
common femoral, and popliteal arteries (P2-3 segments). A
computed tomography or magnetic resonance imaging
angiography study (57 vs 38, respectively) was performed
for preoperative evaluation to identify the patients with
TASC-II D femoropopliteal lesions. All enrolled patients
were free of inflow disease and this did not affect patency
and limb salvage rates.
Procedures. Procedures in both groups were per-
formed in a hybrid operating theater by our team of vascu-
lar surgeons. All patients received local anesthesia in addi-
tion to conscious sedation, when needed. A loading dose of
Table I. Baseline characteristics of the study population
Variable
RE
(n  51)
No. (%)
ENDO
(n  44)
No. (%) P
Sex .90
Male 33 (65) 29 (66)
Female 18 (35) 15 (34)
Age 65 years 34 (67) 31 (71) .69
Comorbidities and risk factors
Diabetes 23 (45) 16 (37) .39
Hypercholesterolemia 24 (48) 17 (39) .41
Hypertension 35 (68) 33 (75) .48
Renal failurea 7 (14) 8 (19) .55
Smoking (current or recent) 36 (71) 33 (76) .62
CLI (Rutherford 4) 25 (49) 18 (41) .43
Gangrene (Rutherford 5) 6 (11.8) 5 (11.4) .95
CLI, Critical limb ischemia; ENDO, endovascular treatment; RE, remote
endarterectomy.
aDefined as creatinine 1.5 mg/dL.clopidogrel (300 mg) was administered before the proce- mure, and patients were maintained on 75 mg/d clopi-
ogrel for a minimum of 6 months with 100 mg/d aspirin.
Outcomes. Complete technical success was defined
s 30% residual stenosis on completion angiography.
he primary end point was the 3-year primary, assisted
rimary, and secondary patency rate. Secondary end
oint was the limb salvage rate. In conformity with the
uidelines by Rutherford et al,15 primary patency was
efined as the absence of restenosis in the treated arterial
egment. Assisted primary patency was achieved by second-
ry endovascular interventions to treat restenoses involving
he originally treated arterial segment. Secondary patency
as achieved with additional procedures to treat the reoc-
lusion.
Patency was evaluated by duplex ultrasound (DUS)
maging, and recurrent stenosis was defined by a focal
tep-up in peak systolic velocity 2.5-fold or an end-
iastolic velocity 60 cm/s.15 Continued patency was
efined as the lack of a recurrent stenosis50% diameter by
US imaging. DUS imaging that revealed a significant
estenosis or reocclusion was verified by additional com-
uted tomography angiography or angiography.
Hemodynamic measures of restenosis or reocclusion
ere performed in resting patients and after exercise
hrough ankle-brachial index (ABI) and pulse volume re-
ordings. Hemodynamic failure was defined as inability of
n ischemic ulcer to heal or an increase in ABI 0.15.
Success was evaluated with the use of anatomic, hemo-
ynamic, and clinical criteria.15 Follow-up assessments
ere within 30 days, after 1, 3, and 6 months through 12
onths, and every 6 months thereafter, with at least 3 years
f follow-up. Surveillance included clinical examination,
BI, and complete arterial Doppler US imaging.
RE procedure. The SFA was exposed through a
mall groin incision. Heparin (70-100 IU/kg) was ad-
inistered immediately before the transversal arteriot-
my at the SFA origin. A 2- to 4-cm distally extended
ndarterectomy was commenced in the standard intra-
able II. Study results
ariable
RE
(n  51)
No. (%)
ENDO
(n  44)
No. (%) P
echnical success 49 (96) 41 (93) .5
omplications 3 (6)a 2 (5)b
arly discharge .0001
Post-op day 1 36 (91)
Post-op day 2 44 (86)
imb salvage 50 (98) 42 (95) .48
mprovement
Rutherford class 41 (80) 28 (64) .079
Postexercise ABI (0.3) 42 (82) 31 (70) .18
BI, Ankle-brachial index; ENDO, endovascular treatment; RE, remote
ndarterectomy.
Seroma, femoral pseudoaneurysm, superficial femoral artery acute oc-
lusion.
Femoral pseudoaneurysm, pulmonary edema.edia cleavage plane to prepare the RE; then, the core
JOURNAL OF VASCULAR SURGERY
December 20121600 Gabrielli et alFig 1. Survival curve analysis demonstrates primary patency at 36 months after remote endarterectomy (RE) and
endovascular (ENDO) treatment. CI, Confidence interval; HR, hazard ratio; SEM, standard error of the mean.Fig 2. Survival curve analysis demonstrates assisted primary patency at 36 months after remote endarterectomy (RE)
and endovascular (ENDO) treatment. CI, Confidence interval; HR, hazard ratio; SEM, standard error of the mean.
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 6 Gabrielli et al 1601Fig 3. Survival curve analysis demonstrates secondary patency at 36 months after remote endarterectomy (RE) and
endovascular (ENDO) treatment. CI, Confidence interval; HR, hazard ratio; SEM, standard error of the mean.Fig 4. Survival curve analysis demonstrates the limb salvage rate at 36 months after remote endarterectomy (RE) and
endovascular (ENDO) treatment. CI, Confidence interval; HR, hazard ratio.
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December 20121602 Gabrielli et alwas threaded into the loop of an appropriately sized
Vollmar Stripper (Aesculap, San Jose, Calif) and ad-
vanced distally to the SFA end point under fluoroscopic
guidance. The entire plaque was transected and removed. A
patent femoral popliteal segment was confirmed and the
end point was defined by arteriography.
Under fluoroscopic guidance, placement of a self-expanding
nitinol stent (Protégé EverFlex Self-Expanding Peripheral
Stent System; ev3 Endovascular Inc, Plymouth, Minn) was
performed across the end point, tacking down the distal
plaque to prevent further dissection. Standard procedure
was used to close the arteriotomy.
Endovascular intervention. Femoral access was per-
formed using 6F sheaths through an ipsilateral anterograde
approach in 65% and through a contralateral retrograde
approach in the remaining patients. Heparin was infused,
and the lesion was crossed with a 0.035-inch wire (Terumo
Medical Corp, Somerset, NJ) through a 5F Bern in a
subintimal way. An Outback LTD re-entry device (Cordis
Endovascular, Warren, NJ) was used to gain access to the
flow lumen (where needed). Angiography was used to
confirm re-entry into the luminal space beyond the lesion
before balloon angioplasty and stenting. Balloon angio-
plasty was subsequently performed with a noncompliant
balloon for the SFA and a semicompliant balloon (various
manufacturers) for popliteal artery lesions to minimize
artery dissection. Nominal inflations were maintained for a
minimum of 2 minutes. All stents used were nitinol self-
expanding stents (ev3 Protégé EverFlex Self-Expanding
Peripheral Stent System). Access site closure was performed
using manual compression.
In both groups, the type of self-expanding nitinol stent
selected was determined by available inventory and opera-
tor preference. Balloon and stent diameter was selected
based on the angiographic measurements of the nondis-
eased artery proximal and distal to the lesion. Stents were
routinely postdilated. If more than one stent was required
to treat a single lesion, a minimum of 1 cm overlap was
used.
Statistical analysis. Categoric data were analyzed
with 2, and time to event provided two-sided P values with
a significance level of .05 and 95% confidence intervals
(CIs).
Primary and secondary patency at the preplanned follow-
Table III. Univariate and multivariate analysis of factors a
Risk factors ENDO
Hypercholesterolemia 0.19 (0.07-0.52)
Diabetes 0.18 (0.06-0.51)
CLI 0.25 (0.09-0.64)
Smoking 1.1 (0.35-3.6)
Hypertension 0.98 (0.35-2.79)
ABI score 60.40 (16.85-216)
ABI,Ankle-brachial index;CI, confidence interval;CLI, critical limb ischemiup was described through the Kaplan-Meier curves. A iog-rank test was performed for comparison of the RE and
NDO procedures. Patency percentages are presented
ith the standard error of the mean. The hazard ratio (HR)
nd 95% CIs were calculated for individual factors in a Cox
nivariate analysis. Factors with P  .05 in this analysis
ere used in a multivariate Cox regression model to deter-
ine predictors for the primary patency. All calculations
ere done by MedCalc 11.1.1.0 software (MedCalc Soft-
are, Mariakerke, Belgium).
ESULTS
The median follow-up was 52.5 months (range, 35-75
onths) in the RE group and 51.2 months (range, 37-69
onths) in the ENDO group. Five RE patients and four
NDO patients were lost to follow-up (censored). The
roups were balanced for age, sex, atherosclerotic risk
actors, and comorbidities (Table I). Technical success,
ospital length of stay, and postoperative complications
ere comparable between groups.
Technical success was achieved in 96% of RE patients
nd in 93% of ENDO patients (P  .91). There were no
erioperative deaths. Immediate complications occurred in
wo ENDOpatients, comprising a large hematoma (access-
elated complication) in one patient that required a
lood transfusion and subsequent US-guided thrombin
emoral pseudoaneurysm treatment, and flash pulmonary
dema in the other patient, who required intubation.
arly complications included femoral artery thromboses
12 hours in one RE patient, which required embolec-
omy and intraoperative thrombolysis. One groin infec-
ion with pseudoaneurysm formation was treated by resec-
ion and saphenous vein patch closure to preserve
ndarterectomy patency. One seroma was treated with a
onservative approach (Table II).
Ninety-one percent of ENDOpatients were discharged
n postoperative day 1, and 86% of the RE group were
ischarged on postoperative day 2. Median hospital length
f stay was 1.4 days for ENDO (range, 1-9 days) compared
ith 2.8 days for RE (range, 2-1 days; P .0001; Table II).
During the follow-up period, 17 limbs in the RE group
xperienced restenosis (six) or occlusions (11), and seven
estenoses and 13 reocclusions were recorded in the
NDO group.
The primary 12-month patency rate was 78.4% 5.7%
ated with restenosis or occlusion
nivariate analysis, HR (95% CI)
P RE P
.001 0.23 (0.07-0.67) .007
.001 0.56 (0.19-1.63) .29
.004 0.16 (0.04-0.57) .004
.8 0.49 (0.15-1.62) .02
.98 0.60 (0.19-1.87) .38
.0001 37.58 (8.86-158.92) .0001
O, endovascular treatment;HR, hazard ratio;RE, remote endarterectomy.ssoci
Un RE (40 of 51) vs 59.1%  7.2% in ENDO (26 of 44)
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Volume 56, Number 6 Gabrielli et al 1603patients. The primary 12-month patency HR was 2.1 (95%
CI, 0.99-4.45; P  .05). The 24-month primary patency
(fifth follow-up) was 76.5%  5.9% in RE (39 of 51) and
56.8%  7.4% in ENDO (25 of 44) patients. The corre-
sponding HR was 2.6 (95% CI, 0.99-4.2; P  .05). The
36-month primary patency (seventh follow-up) was 62.7%
(32 of 51) in RE and 47.7% (21 of 44) in ENDO patients
(HR, 1.89; 95% CI, 0.94-3.78; P  .07; Fig 1).
During the follow-up period, 37 limbs underwent re-
intervention, in all cases, a finding consistent with resteno-
sis or occlusion before reintervention was recorded by
Doppler US.
In the RE group, we recorded 11 reocclusions and six
restenoses; 16 patients underwent repeat treatment. Two
of the reocclusions were treated with thrombolysis, fol-
lowed by PTA and stenting; at the 36-month follow-up,
one was still patent. Five patients underwent SFA throm-
bectomy (three remained patent); in four patients, this was
followed by stenting. One patient required above-knee
amputation because of persistent ischemia and advanced
necrosis. In the remaining two patients, a subintimal angio-
plasty was performed, and one remained patent. One oc-
clusion did not require reintervention; this patient pre-
sented with mild intermittent claudication only. Three
patients with reocclusion after the reintervention re-
ceived an infragenicular bypass, and one reocclusion was
recorded and no reintervention was needed for mild,
associated symptoms. The six restenoses were treated by
PTA. Two of these were still patent at the 36-month
follow-up, and one restenosis was followed by another
intervention (infragenicular bypass).
In the ENDO group, we recorded 13 reocclusions and
seven restenoses, and 18 of these were re-treated. Five
reocclusions were treated with thrombolysis, followed by
PTA and stenting; one of these was patent. Seven patients
with reocclusion underwent subintimal angioplasty (two of
these were patent), and two required above-knee amputa-
tion because of persistent ischemia. One patient with mild,
intermittent claudication did not undergo reintervention.
Six of the seven SFAs with restenosis were treated with
PTA; two were patent, and one was followed by another
intervention (infragenicular bypass). Seven patients with
reocclusion after the reintervention received an infra-
Table III. Continued.
Risk factors
M
ENDO P
Hypercholesterolemia 0.24 (0.07-0.81) .02
Diabetes 0.13 (0.02-0.64) .01
CLI 0.01 (0.003-0.08) .0001
Smoking . . . . . .
Hypertension . . . . . .
ABI score . . . . . .genicular bypass, with reocclusion in two cases. 0The assisted primary patency rate at 36 months was
6.6% 6.4% in RE patients (34 of 51) and 52.3% 7.5%
n ENDO patients (23 of 44; HR, 2.45; 95% CI, 1.20-
.02; P  .01; Fig 2).
Secondary patency overlapped the primary comparison
ata at 12 and 24 months, and there was a slight but
ignificative advantage for the RE at 36 months. The sec-
ndary patency rate by survival curve analysis was 72.5% 
.2% in RE patients (37 of 51) and 54.5% 7.5% in ENDO
atients (24 of 44; HR. 2.4; 95% CI, 1.13-5.11; P  .02;
ig 3).
An unplanned subgroups analysis on Rutherford 4 to 5
ombined groups showed patency rates were significantly
etter in RE groups in all the analyses. The primary patency
ate at 36 months in Rutherford 4 to 5 patients was 52%
.6% in RE patients (16 of 31) vs 26%  9.9% in ENDO
atients (six of 23; HR, 2.1; 95% CI, 0.99-4.64; P  .05).
he assisted primary patency rate at 36 months in Ruther-
ord 4 to 5 patients was 58%  9.2% in RE patients (18 of
1) and 30%  10% in ENDO patients (seven of 23; HR,
.7; 95% CI, 1.20-6.23; P .01). Secondary patency rates
t 36 months in Rutherford 4 to 5 patients was 61% 9.5%
n RE patients (19 of 31) and 35%10% in ENDOpatients
eight of 23; HR, 2.7; 95% CI, 1.17-6.47; P  .01).
Limb salvage after 3 years of follow-up was 98% in the
E group and 95% in ENDO, with three above-knee
mputations (HR, 2.64; 95% CI, 0.26-26.06; P  .4; Fig
). The limb salvage rate in Rutherford 4 to 5 patients after
years of follow-up was 96.7% in the RE group (30 of 31)
nd 91% in the ENDO group (21 of 23), with three
bove-knee amputations. The 36-month limb salvage HR
as 3.56 (95% CI, 0.34-37.22; P  .2).
Rutherford classification and significant postexercise
BI improvements (0.2) after 3 years of follow-up were
ecorded, respectively, in 80% and 64% (P  .079) of RE
nd in 82% and 70% of ENDO patients (P  .18).
Cox univariate analysis showed that hypercholesterol-
mia in ENDO (HR, 0.19; 95% CI, 0.075-0.52; P .001)
nd RE (HR, 0.23; 95% CI, 0.070-0.67; P  .007) and
resence of CLI in ENDO (HR, 0.23; 95% CI, 0.09-0.61;
 .003) and RE (HR, 0.11; 95% CI, 0.04-0.34; P 
0001) were significantly associated with decreased pa-
ency. Diabetes was significant in the ENDO group (HR,
ariate analysis, HR (95% CI)
RE P RE vs ENDO P
0 (0.02-0.37) .0007 2.95 (1.37-6.32) .005
. . . . . . . . . . . .
9 (0.05-0.70) .01 5.6 (2.08-15.04) .0006
. . . . . . . . . . . .
. . . . . . . . . . . .
. . . . . . . . . . . .ultiv
0.1
0.1.18; 95% CI, 0.063-0.52; P  .001). Cox multivariate
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December 20121604 Gabrielli et alanalysis showed hypercholesterolemia and CLI were inde-
pendent predictors of patency (Table III).
DISCUSSION
RE with distal end point stenting is a less invasive
alternative to bypass in patients with complete long-
segment SFA occlusion.16-19 Documented advantages of
RE are reduced hospitalization, preservation of bypass op-
tions, decreased morbidity, and lower incidence of limb-
threatening ischemia when RE is unsuccessful. Notwith-
standing advanced endovascular techniques and the
availability of new devices, which have allowed treatment of
an increasing number of patients with femoropopliteal
occlusive disease, long-term results remain to be defined in
prospective cohorts. Currently, the best therapeutic ap-
proach for extended femoropopliteal occlusive disease con-
tinues to be debated.
Moreover, the TASC-II committee redefined the rec-
ommendations for revascularization approach. Endovascu-
lar therapy represents the treatment of choice in TASC A
and B lesions and is recommended in TASC C when
comorbidities are present; surgical therapy (bypass) is rec-
ommended for TASC D lesions.6 To date, endovascular
technique offers immediate improvement in functional sta-
tus with shorter recovery, whereas surgical bypass usually
needs a longer stay. However, data from literature on
minimally invasive treatment of TASC D lesions are poor,
and the outcomes have been usually described to be
strongly surgeon-dependent, with no operative mortality
and minimal morbidity. In this scenario, RE with distal
stenting could offer a potentially less invasive alternative in
patients who need a vascular reconstruction for longer
occlusions of the SFA. The safety of both procedures has
been demonstrated, and their outcomes significantly con-
tribute to patient satisfaction.20-25 On the basis of these
observations, TASC classification and treatment guidelines
seem to no longer adhere to the need for surgical interven-
tion in advanced lesions.
Our study is the first published prospective trial to show
a slight but significant advantage in patency in TASC-II D
occlusive lesions when treated with RE compared with an
endovascular procedure alone, which, however, is associ-
ated with lower primary and secondary patency rates. Our
results in the RE group are in line with those previously
demonstrated by several authors12,15-17,26-29 but seem to
be significantly better than others.30 These differences
could be partially explained by an increased number of
patients with diabetes (59%), dyslipidemia (41%), and
chronic renal failure in these series26 and by the use of
different stent grafts.14
Our study demonstrated that the endovascular and RE
procedures were both feasible and safe. The two groups did
not differ in associated major complications, limb salvage,
Rutherford category, or ABI improvement. However,
there was a significant difference for hospital length of stay;
in fact, most patients in the ENDO group were discharged
the day after recovery, whereas RE patients required at least
2 nights of recovery. RAn interesting finding is that the post hoc unplanned
nalysis on combined Rutherford 4 and 5 patients demon-
trated a significative advantage in RE vs ENDO in patency
ates. This confirmed that the surgical approach remained
he treatment of choice in those patient groups and reflects
he real-world practice in which surgical bypass is the
ainstay approach.
Comorbidities, such as diabetes,31 dyslipidemia, renal
ailure, and CLI,32 have been described as being signifi-
antly associated with more advanced arterial occlusive
isease and endovascular treatment, resulting in a worse
utcome. Our multivariate analysis results confirmed that
ypercholesterolemia and CLI only are significant predic-
ors of reocclusion. Diabetes seems to be significant only in
he ENDO group, but the small sample number limited
efinitive conclusions. However, these data have to be
trongly taken into account when the preoperative evalua-
ion is performed to address the best surgical approach.
ata from literature on primary and secondary patency
esults encourage the use of RE, even in unfit patients who
ere described as being ineligible for major surgery.33,34
ur results on the safety and feasibility encourage further
nvestigation of patients unfit for surgery who could benefit
rom RE as the first treatment of choice.
ONCLUSIONS
Despite published data that indicate surgery is the first
reatment choice in TASC-II D lesions, we have demon-
trated that these lesions can also benefit from an endovas-
ular or hybrid approach. However, we note that although
ssociated morbidity remains low, the primary and second-
ry patency rates after endovascular procedures appear to be
ower than the rates after RE. CLI (Rutherford 4-5) and
ypercholesterolemia represent detrimental risk factors for
eocclusion; thus, adjuvant therapy, such as with aspirin,
lopidogrel, and statin agents, may improve the outcomes
nd deserves further investigation. Endovascular proce-
ures and RE may both be performed through minimally
nvasive techniques.
Our results represent the first demonstration in a pro-
pective trial that RE offers better outcomes in patency than
n endovascular approach and encourage further prospec-
ive study to compare RE with infragenicular bypass in
ASC-II D patients with CLI.
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